Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Chalazion 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Pilonidal Sinus 1Fistula 1Disease Progression 1

Interventions

Lenalidomide 4Bortezomib 4Dexamethasone 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Doxorubicin 2tremelimumab 1tivozanib 1ricolinostat 1pomalidomide 1pazopanib 1nilotinib 1durvalumab 1avelumab 1abexinostat 1Transplantation, Autologous 1Tamoxifen 1Steroids 1Standard of Care 1Practice Guidelines as Topic 1Parenteral Nutrition 1Palliative Care 1Paclitaxel 1Nivolumab 1NVP-BKM120 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Disease Progression × Conservative Treatment × Clear all
NCT02522585 2016-04-20

p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management

Parc de Salut Mar

Completed
100 enrolled
Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡